Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu Vaccine's hidden power: boosting nose immunity?

NCT ID NCT06824779

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the flu vaccine changes immune cells in the nose and blood. Researchers will collect samples from 30 healthy adults before and after they get the flu shot. The goal is to understand if the vaccine creates 'resident memory' immune cells in the nose, which could block the flu virus at its entry point.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Flu vaccine
What this could lead to
If successful, this study could help design better flu vaccines that boost immunity right where the virus enters—the nose.
What could go wrong
This is a small, early-stage observational study with only 30 participants. It measures immune markers, not actual protection, so results may not lead to immediate changes in vaccination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Affiliated to the Social Security System * Signed informed consent form * Having decided to be vaccinated against the flu Exclusion Criteria: * History of recurrent nosebleeds or systemic hemorrhages * Previous injury or surgery which modified nasal cavity (e.g. deviated nasal septum) * Individuals receiving anticoagulant therapy * Individuals who experienced a severe respiratory infection leading to hospitalization in the last 6 months * Individuals who received an antibiotic therapy for respiratory infection or any other infection in the last 6 months * Immunocompromised individuals, or individuals taking immunosuppressed therapy or having a pathology (chronic infection, auto-immune disease) which could impact on immunity based on investigator's opinion * Allergy to any component of the vaccines used in the study * Unstable chronic pathology * People deprived of liberty or hospitalized without any consent * People under guardianship (authorship or curators) * Individuals who received a vaccine (any vaccine) in the last 30 days * Pregnant or breast-feeding people * Individuals experiencing respiratory infection symptoms. Inclusion will be postponed up to 7 days after the symptom resolution * People with no command of the French language

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Flu vaccine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Flu vaccine Volunteers

Contacts and locations

Locations

  • CHU de Saint-Etienne

    Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.